Renaissance Capital logo

Finch Therapeutics Group Priced, Nasdaq: FNCH

Phase 3-ready biotech developing microbiome therapeutics.

Industry: Health Care

Latest Trade: $1.94 0.00 (0.0%)

First Day Return: +25.4%

Return from IPO: -99.6%

Industry: Health Care

We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Our Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Our lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection, or CDI. In June 2020, we reported positive topline data from our first of two pivotal trials in recurrent CDI, and we plan to initiate a Phase 3 clinical trial, which we refer to as PRISM4, as our second pivotal trial of CP101 for recurrent CDI in mid-2021.
more less
IPO Data
IPO File Date 02/26/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.5
Deal Size ($mm) $128
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/18/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.5
Deal Size ($mm) $128
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Jefferies
more
Company Data
Headquarters Somerville, MA, United States
Founded 2014
Employees 131
Website www.finchtherapeutics.com

Finch Therapeutics Group (FNCH) Performance